Prognostic Significance of Reck in Ameloblastoma and Ameloblastic Carcinoma

Background- Ameloblastoma is a benign aggressive neoplasm of odontogenic epithelium. It has a high rate of recurrence, occasional metastasis and malignant transformation. Reversion-inducing cysteine rich protein with kazal motifs (RECK) gene is a tumour suppressor gene expressed in various normal organs and has been found to be important in suppressing tumour invasion, metastasis and angiogenesis. RECK levels are significantly down regulated in many tumours compared with the adjacent normal tissue and detection of normal or elevated RECK levels in tumour samples has been associated with decreased invasiveness and metastatic potential, with improved prognosis. Poor clinical prognosis in ameloblastoma may be associated with decreased RECK expressions. The aim of this study was to assess the prognostic significance of RECK in ameloblastoma and ameloblastic carcinoma, by determining expression of RECK protein.
Methods- Selected Paraffin blocks of 50 ameloblastoma cases, 8 ameloblastic carcinoma cases and 50 control cases (pyogenic granuloma) were sectioned and stained with commercial antibodies for RECK. Immunohistochemical staining of stromal and tumour cells in individual cases and study controls was assessed at X100 magnification to obtain a quantified combined score for each one. Proportion of cases with positive expression of RECK were compared between ameloblastoma and ameloblastic carcinoma, using chi square statistics. Mean scores for RECK expression in ameloblastoma and ameloblastic carcinoma cases were compared with that of the control group using the ANOVA test.
Results- RECK was positive in a greater proportion of ameloblastoma (96%) than ameloblastic carcinoma (87.5%) than in control cases (80%) (p = 0.049). The mean score of RECK expression in Ameloblastoma was higher than Ameloblastic carcinomas. The mean score of RECK expression was also higher in unicystic ameloblastoma than solid multicystic ameloblastoma.
Conclusion- RECK may be a promising prognostic marker in ameloblastoma and ameloblastic carcinoma.

Prognostic, epithelium, Ameloblastoma, Ameloblastic

1. Regezi JA Scuibba J, Jordan C. (Eds.). Odontogenic Tumors. Oral Pathology:Clinico pathologic correlations. 5th edition, Saunders Elsevier; 2003: 265-270. [Google Scholar] [Crossref]

2. Guerrisi M, Piloni MJ, Keszler A. Odontogenic tumors in children and adolescents. A 15-year retrospective study in Argentina. Medicina Oral, Patologia Oral y Cirugia Bucal. 2007;12(3):E180-185. [Google Scholar] [Crossref]

3. Fletcher DM. (Ed.). Odontogenic Tumors. Diagnostic Histopathology of Tumors. 2nd edition, Churchill livingstone; 2000: 217-220. [Google Scholar] [Crossref]

4. WHO Classification of Tumours Editorial Board. Head and neck tumours [Internet; beta version ahead of print]. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 9). Available from: https://tumourclassification.iarc.who.int/chapters/52. [Google Scholar] [Crossref]

5. Ladeinde AL, Ajayi OF, Ogunlewe MO, Adeyemo WL, Arotiba GT, Bamgbose BO, et al. Odontogenic tumors: a review of 319 cases in a Nigerian teaching hospital. Oral Surgery, Oral Medicine, Oral Pathology, Oral adiology, and Endodontics. 2005;99(2):191-195. [Google Scholar] [Crossref]

6. Hendra FN, Van Cann EM, Helder MN, et al. Global incidence and profile of ameloblastoma: A systematic review and meta-analysis. Oral Dis. 2020; 26: 12–21. [Google Scholar] [Crossref]

7. Akinshipo AW, Sivaramakrishnan G, Enwuchola J, Effiom O, Adeoye J, Ramanathan A, Chaurasia A. Unraveling the Mysteries of Ameloblastoma in African Population: A Comprehensive Analysis of 371 Cases from Clinical, Radiological, and Histopathological Perspectives. Head Neck Pathol. 2025; Jan 7; 19(1):2. [Google Scholar] [Crossref]

8. Intapa C. Analysis of Prevalence and Clinical Features of Ameloblastoma and its Histopathological Subtypes in Southeast Myanmar and Lower Northern Thailand Populations: A 13-Year Retrospective Study. J Clin Diagn Res. 2017 Jan;11(1):ZC102-ZC106. [Google Scholar] [Crossref]

9. Mendenhall WM, Werning JW, Fernandes R, Malyapa RS, Mendenhall NP. Ameloblastoma. American Journal of Clinical Oncology. 2007;30(6):645-648. [Google Scholar] [Crossref]

10. Kumamoto H. Molecular pathology of odontogenic tumors. Journal of Oral Pathology & Medicine. 2006;35(2):65-74. [Google Scholar] [Crossref]

11. Heikinheimo K, Jee KJ, Niini T, Aalto Y, Happonen RP, Leivo I, et al. Gene expression profiling of ameloblastoma and human tooth germ by means of a cDNA microarray. Journal of Dental Research. 2002;81(8):525-530. [Google Scholar] [Crossref]

12. .Owosho AA, Ladeji AM, Adebiyi KE, Olajide MA, Okoye ISI, Kehinde T, Nwizu NN, Summersgill KF. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution. Eur Arch Otorhinolaryngol. 2021 Aug; 278(8):3065-3071. [Google Scholar] [Crossref]

13. Zhang B, Zhang J, Xu ZY, Xie HL. Expression of RECK and matrix metalloproteinase-2 in ameloblastoma. BMC Cancer. 2009;9:427. [Google Scholar] [Crossref]

14. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: a review. Critical reviews in Oral Biology and Medicine. 1993;4(2):197-250. [Google Scholar] [Crossref]

15. Kumamoto H, Yamauchi K, Yoshida M, Ooya K. Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas. Journal of Oral Pathology & Medicine. 2003;32(2):114-120. [Google Scholar] [Crossref]

16. Nonaka CF, Augusto Vianna Goulart Filho J, Cristina da Costa Miguel M, Batista de Souza L, Pereira Pinto L. Immunohistochemical expression of matrix metalloproteinases 1, 2, and 9 in odontogenic myxoma and dental germ papilla. Pathology, Research and Practice. 2009;205(7):458-465. [Google Scholar] [Crossref]

17. Cavalcante RB, Pereira KM, Nonaka CF, Nogueira RL, de Souza LB. Immunohistochemical expression of MMPs 1, 7, and 26 in syndrome and non-syndrome odontogenic keratocysts. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 2008;106(1):99-105. [Google Scholar] [Crossref]

18. Kumamoto H, Ooya K. Immunohistochemical detection of MT1-MMP, RECK, and EMMPRIN in ameloblastic tumors. Journal of Oral Pathology & Medicine. 2006;35(6):345-351. [Google Scholar] [Crossref]

19. Bast BT, Pogrel MA, Regezi JA. The expression of apoptotic proteins and matrix metalloproteinases in odontogenic myxomas. Journal of Oral and Maxillofacial Surgery. 2003;61(12):1463-1466. [Google Scholar] [Crossref]

20. Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, Koyama F, et al. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clinical Cancer Research. 2004;10(16):5572-5579. [Google Scholar] [Crossref]

21. Furumoto K, Arii S, Mori A, Furuyama H, Gorrin Rivas MJ, Nakao T, et al. RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing--cysteine-rich protein with Kazal motifs. Hepatology. 2001;33(1):189-195. [Google Scholar] [Crossref]

22. Span PN, Sweep CG, Manders P, Beex LV, Leppert D, Lindberg RL. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma. Cancer. 2003;97(11):2710-2715. [Google Scholar] [Crossref]

23. Masui T, Doi R, Koshiba T, Fujimoto K, Tsuji S, Nakajima S, et al. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clinical Cancer Research. 2003;9(5):1779-1784. [Google Scholar] [Crossref]

24. Lau SL, Samman N. Recurrence related to treatment modalities of unicystic ameloblastoma: a systematic review. International Journal of Oral and Maxillofacial Surgery. 2006;35(8):681-690. [Google Scholar] [Crossref]

25. Olaitan AA, Adekeye EO. Unicystic ameloblastoma of the mandible: a long-term follow-up. Journal of Oral and Maxillofacial Surgery. 1997;55(4):345-348; discussion 349-350. [Google Scholar] [Crossref]

26. Zhang B, Zhang J, Xu ZY, Xie HL. Expression of RECK and matrix metalloproteinase-2 in ameloblastoma. BMC Cancer. 2009;9:427. [Google Scholar] [Crossref]

27. Cardeal LB, Boccardo E, Termini L, Rabachini T, Andreoli MA, di Loreto C, et al. HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis. PloS One. 2012;7(3):e33585. [Google Scholar] [Crossref]

28. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumour tissue specimens and in cell lines with different metastatic potential. BMC Cancer. 2009;9:20. [Google Scholar] [Crossref]

29. Zhang, Y., Cheng, S., Zhang, G., Ma, W., Liu, Y., Zhao, R., Zhang, Q. and Pang, D. Low expression of RECK indicates a shorter survival for patients with invasive breast cancer. Cancer Sci. 2012; 103: 1084-1089. [Google Scholar] [Crossref]

• “Improving Laboratory Operations and Patient Care through Total Laboratory Automation”
• Demographic Profile of Biologic Types of Ameloblatoma and Ameloblastic Carcinoma Seen in a Nigerian Population
• “From Gut to Gonads: A Rare Journey of Jejunal Neuroendocrine Tumor to the Testis”